PET-CT evaluation of the curative effect of crizotinib on malignant myofibroblastoma with rare mutation of ALK R401: a case report and literature review

References

• HadjigeorgiouGFSamarasVVarsosVLow-grade myofibroblastic sarcoma of the thoracic spine: report of an extreme rare caseBr J Neurosurg201731673173327535494
   PubMed Web of Science ®Google Scholar
• SchurchWSeemayerTAGabbianiGThe myofibroblast: a quarter century after its discoveryAm J Surg Pathol19982221411479500214
   PubMed Web of Science ®Google Scholar
• JoVYFletcherCDWHO classification of soft tissue tumours: an update based on the 2013 (4th) editionPathology20144629510424378391
   PubMed Web of Science ®Google Scholar
• SinghSKRahejaAAJagdevanAKSinghPKPurkaitSSuriVAMalignant temporal muscle myofibroblastoma with an early recurrence in a childNeurol India201765240841028290416
   PubMed Web of Science ®Google Scholar
• HumphriesWE3rdSatyanKBRelyeaKLow-grade myofibroblastic sarcoma of the sacrumJ Neurosurg Pediatr20106328629020809714
   PubMed Web of Science ®Google Scholar
• MajnoGThe story of the myofibroblastsAm J Surg Pathol197936535542534390
   PubMed Web of Science ®Google Scholar
• StarkMHoffmannAXiongZMammary myofibrosarcoma: case report and literature reviewBreast J201117330030421545434
   PubMed Web of Science ®Google Scholar
• MontgomeryEAShusterDDBurkartALInflammatory myofibroblastic tumors of the urinary tract: a clinicopathologic study of 46 cases, including a malignant example inflammatory fibrosarcoma and a subset associated with high-grade urothelial carcinomaAm J Surg Pathol200630121502151217122505
   PubMed Web of Science ®Google Scholar
• SukovWRChevilleJCCarlsonAWUtility of ALK-1 protein expression and ALK rearrangements in distinguishing inflammatory myofibroblastic tumor from malignant spindle cell lesions of the urinary bladderMod Pathol200720559260317396140
   PubMed Web of Science ®Google Scholar
• LuZJZhouSHYanSXYaoHTAnaplastic lymphoma kinase expression and prognosis in inflammatory myofibroblastic tumours of the maxillary sinusJ Int Med Res20093762000200820146901
   PubMed Web of Science ®Google Scholar
• QiuXMontgomeryESunBInflammatory myofibroblastic tumor and low-grade myofibroblastic sarcoma: a comparative study of clinicopathologic features and further observations on the immunohistochemical profile of myofibroblastsHum Pathol200839684685618400254
   PubMed Web of Science ®Google Scholar
• YauNKFongAYLeungHFA pan-cancer review of ALK mutations: implications for carcinogenesis and therapyCurr Cancer Drug Targets201515432733625714698
   PubMed Web of Science ®Google Scholar
• ChoiHRole of imaging in response assessment and individualised treatment for sarcomasClin Oncol (R Coll Radiol)201729848148828506521
   PubMed Web of Science ®Google Scholar
• RiedlCCPinkerKUlanerGAComparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancerEur J Nucl Med Mol Imaging20174491428143728462446
   PubMed Web of Science ®Google Scholar
• TherassePArbuckSGEisenhauerEANew guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of CanadaJ Natl Cancer Inst200092320521610655437
   PubMed Web of Science ®Google Scholar
• BangJILimYPaengJCComparison of quantitative methods on FDG PET/CT for treatment response evaluation of metastatic colorectal cancerNucl Med Mol Imaging201751214715328559939
   PubMed Web of Science ®Google Scholar
• SchaferJFGatidisSSchmidtHSimultaneous whole-body PET/MR imaging in comparison to PET/CT in pediatric oncology: initial resultsRadiology2014273122023124877983
   PubMed Web of Science ®Google Scholar
• Ben BouallegueFTabaaYAKafrouniMCartronGVauchotFMariano-GoulartDAssociation between textural and morphological tumor indices on baseline PET-CT and early metabolic response on interim PET-CT in bulky malignant lymphomasMed Phys20174494608461928513853
   PubMed Web of Science ®Google Scholar
• ButrynskiJED’AdamoDRHornickJLCrizotinib in ALK-rearranged inflammatory myofibroblastic tumorN Engl J Med2010363181727173320979472
   PubMed Web of Science ®Google Scholar
• LiuQKanYZhaoYHeHKongLEpithelioid inflammatory myofibroblastic sarcoma treated with ALK inhibitor: a case report and review of literatureInt J Clin Exp Pathol2015811153281533226823889
   PubMed Web of Science ®Google Scholar
• YuanCMaMJParkerJVMekhailTMMetastatic anaplastic lymphoma kinase-1 (ALK-1)-rearranged inflammatory myofibroblastic sarcoma to the brain with leptomeningeal involvement: favorable response to serial ALK inhibitors: a case reportAm J Case Rep20171879980428713152
   PubMed Web of Science ®Google Scholar
• CostaDBKobayashiSPandyaSSCSF concentration of the anaplastic lymphoma kinase inhibitor crizotinibJ Clin Oncol20112915e443e44521422405
   PubMed Web of Science ®Google Scholar
• HidaTNokiharaHKondoMAlectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trialLancet201739010089293928501140
   PubMed Web of Science ®Google Scholar
• StefanouDStamatopoulouSSakellaropoulouABevacizumab, pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients: focus on patients with brain metastasesOncol Lett20161264635464228101218
   PubMed Web of Science ®Google Scholar
• AravantinosGPectasidesDBevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic reviewJ Ovarian Res201475724864163
   PubMed Web of Science ®Google Scholar
• HornLSandlerAChemotherapy and antiangiogenic agents in non-small-cell lung cancerClin Lung Cancer20078Suppl 2S68S7317382027
   PubMed Web of Science ®Google Scholar
• TengLSJinKTHeKFWangHHCaoJYuDCAdvances in combination of antiangiogenic agents targeting VEGF-binding and conventional chemotherapy and radiation for cancer treatmentJ Chin Med Assoc201073628128820603084
   PubMed Web of Science ®Google Scholar
• JiangTLiASuCAddition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patientsOncotarget2017837626486265728977977
   PubMedGoogle Scholar
• OtsukaKHataATakeshitaJEGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancerCancer Chemother Pharmacol201576483584126349474
   PubMed Web of Science ®Google Scholar
• KimKRShimHJHwangJEThe role of interim FDG PET-CT after induction chemotherapy as a predictor of concurrent chemoradiotherapy efficacy and prognosis for head and neck cancerEur J Nucl Med Mol Imaging201845217017828940101
   PubMed Web of Science ®Google Scholar
• MatsumotoYBabaSEndoMMetabolic tumor volume by 18F-FDG PET/CT can predict the clinical outcome of primary malignant spine/spinal tumorsBiomed Res Int20172017813267628852650
   PubMed Web of Science ®Google Scholar
• ChoiESHaSGKimHSHaJHPaengJCHanITotal lesion glycolysis by 18F-FDG PET/CT is a reliable predictor of prognosis in soft-tissue sarcomaEur J Nucl Med Mol Imaging201340121836184223880967
   PubMed Web of Science ®Google Scholar